Can any stem-cell paper be trusted?

So, just how untrustworthy is the stem-cell literature? Very, according to one of the field's leading lights, David Shaywitz of the Harvard Stem Cell Institute. He's the author of linkurl:an op-ed piece;http://www.washingtonpost.com/wp-dyn/content/article/2006/01/11/AR2006011102040.html that was meant to defend the beleaguered field of stem-cell research, despite linkurl:fraudulent papers;http://www.the-scientist.com/blog/browse/blogger/13/date/2006-01/ from the lab of Korean researcher Hwang

Written byTabitha M. Powledge
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
So, just how untrustworthy is the stem-cell literature? Very, according to one of the field's leading lights, David Shaywitz of the Harvard Stem Cell Institute. He's the author of linkurl:an op-ed piece;http://www.washingtonpost.com/wp-dyn/content/article/2006/01/11/AR2006011102040.html that was meant to defend the beleaguered field of stem-cell research, despite linkurl:fraudulent papers;http://www.the-scientist.com/blog/browse/blogger/13/date/2006-01/ from the lab of Korean researcher Hwang Woo Suk. But in what was almost an aside, Shaywitz dropped a bombshell:**While most in the field of stem cell research were shocked by the reports of fraud, the shock was only one of degree; it is common knowledge that the bar for publication in this field often has appeared remarkably low, with even well-respected research journals seeming to fall over one another for the privilege of publishing the next hot paper. The result of this frenzy has been an entire body of literature that is viewed with extreme skepticism by most serious stem cell investigators.**It was a bombshell to me, anyway. There is plenty of gossip among science journalists about how the top journals--you know who you are--engage in savage battles to be first with the latest in a handful of hot research fields. And that they define **hot** to mean papers that will grab headlines on TV news and in the New York Times. The Scientist's Ivan Oransky brought this topic up in linkurl:his blog;http://www.the-scientist.com/blog/display/22934/ Tuesday. Scientists grumble too, only not usually for quotation. But this is the first time I've seen a prominent researcher declaring that this unseemly competition has cast doubt--not just on an individual paper or two, but on an entire literature.What is to be done? Must stem-cell researchers conduct their own lab peer review, replicating every bit of each others' work before they try to build on it? Are there structural changes at journals that will help ensure that papers are reporting accurately? The editor of Science, linkurl:Donald Kennedy, says;http://www.sciencemag.org/sciext/hwang2005/kennedy_20060110_transcript.pdf his journal (which published the two fraudulent Hwang papers, now retracted) is considering adding some measures such as improved image analysis. But overall, he doesn't sound optimistic that procedural safeguards will make much difference.Kennedy goes on to argue that such cases are rare. But that's just the point. If we are to believe Shaywitz, in stem-cell research at least, they are not rare at all.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies